

David M Goldenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11904539/publications.pdf>

Version: 2024-02-01

457
papers

24,417
citations

6254

80
h-index

14759

127
g-index

462
all docs

462
docs citations

462
times ranked

13210
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Peptide Camptothecin Drug-linkers for Potent ADCs Letter. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 237-237.	4.1	1
2	Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 954-955.	0.9	11
3	Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1221-1227.	5.0	12
4	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	27.0	601
5	Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases. <i>Biomedicines</i> , 2020, 8, 548.	3.2	8
6	Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1205-1211.	5.0	22
7	Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 871-885.	3.1	57
8	Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer. <i>Oncotarget</i> , 2020, 11, 3849-3862.	1.8	22
9	Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. <i>MAbs</i> , 2019, 11, 987-995.	5.2	74
10	Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches. <i>Frontiers in Medicine</i> , 2019, 6, 124.	2.6	20
11	Sacituzumab Govitecan-hzyi in Refractory Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 741-751.	27.0	542
12	A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer. <i>EJNMMI Research</i> , 2019, 9, 86.	2.5	4
13	Carcinoembryonic antigen-targeted photodynamic therapy in colorectal cancer models. <i>EJNMMI Research</i> , 2019, 9, 108.	2.5	7
14	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 763-773.	5.6	49
15	Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130). <i>Molecular Cancer Therapeutics</i> , 2018, 17, 196-203.	4.1	24
16	IMMU-140, a Novel SN-38 Antibody Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 150-160.	4.1	20
17	The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. <i>Oncotarget</i> , 2018, 9, 28989-29006.	1.8	169
18	Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. <i>Gynecologic Oncology Reports</i> , 2018, 25, 37-40.	0.6	15

#	ARTICLE	IF	CITATIONS
19	Sensitivity of pretargeted immunoPET using ⁶⁸ Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with ¹⁸ F-FDG PET-CT. <i>Oncotarget</i> , 2018, 9, 27502-27513.	1.8	12
20	Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3405-3415.	7.0	92
21	¹²⁵ I- Versus ¹²⁵ I-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts. <i>Journal of Nuclear Medicine</i> , 2017, 58, 926-933.	5.0	34
22	Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model. <i>Journal of Nuclear Medicine</i> , 2017, 58, 706-710.	5.0	37
23	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e184-e186.	3.5	6
24	Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. <i>Cancer</i> , 2017, 123, 3843-3854.	4.1	145
25	Consolidation anti-CD22 fractionated radioimmunotherapy with ⁹⁰ Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	4.6	33
26	Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study. <i>Cancer</i> , 2017, 123, 638-649.	4.1	30
27	Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells. <i>Cancer Research</i> , 2017, 77, 5384-5394.	0.9	60
28	Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-1-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. <i>Clinical Cancer Research</i> , 2017, 23, 5711-5719.	7.0	107
29	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2141-2148.	1.6	283
30	Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. <i>Journal of Clinical Oncology</i> , 2017, 35, 2790-2797.	1.6	119
31	Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3338-3346.	1.6	69
32	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 2017, 2141-2148.	1.6	6
33	Enhancing the antitumor potency of T cells redirected by bispecific antibodies. <i>Oncoscience</i> , 2017, 4, 120-121.	2.2	3
34	Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. <i>Haematologica</i> , 2016, 101, 1327-1332.	3.5	9
35	Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸ Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1505-1511.	5.0	61
36	Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1910-1919.	4.1	30

#	ARTICLE	IF	CITATIONS
37	Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opinion on Biological Therapy, 2016, 16, 883-893.	3.1	29
38	Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*. Leukemia and Lymphoma, 2016, 57, 803-811.	1.3	12
39	Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e75-e79.	1.9	80
40	Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).. Journal of Clinical Oncology, 2016, 34, 8559-8559.	1.6	4
41	Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).. Journal of Clinical Oncology, 2016, 34, 9011-9011.	1.6	4
42	The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology, 2015, 169, 701-710.	2.5	31
43	Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatric Blood and Cancer, 2015, 62, 1171-1175.	1.5	89
44	Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*. Oncotarget, 2015, 6, 22496-22512.	1.8	303
45	Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. Frontiers in Medicine, 2015, 2, 84.	2.6	29
46	Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors. Molecular Imaging, 2015, 14, 7290.2015.00015.	1.4	37
47	Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. MAbs, 2015, 7, 199-211.	5.2	17
48	The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmunity Reviews, 2015, 14, 1079-1086.	5.8	59
49	Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clinical Cancer Research, 2015, 21, 5131-5138.	7.0	122
50	A pretargeting system for tumor PET imaging and radioimmunotherapy. Frontiers in Pharmacology, 2015, 6, 54.	3.5	41
51	Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjugate Chemistry, 2015, 26, 919-931.	3.6	184
52	90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematology, the, 2015, 2, e108-e117.	4.6	36
53	Pretargeted ImmunoPET of Prostate Cancer with an Anti-TROP-2 x Anti-HSG Bispecific Antibody in Mice with PC3 Xenografts. Molecular Imaging and Biology, 2015, 17, 94-101.	2.6	17
54	Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Physics, 2015, 2, 5.	2.7	10

#	ARTICLE	IF	CITATIONS
55	First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 3870-3878.	7.0	223
56	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. <i>Haematologica</i> , 2015, 100, e128-e131.	3.5	26
57	90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. <i>European Journal of Cancer</i> , 2015, 51, 1857-1864.	2.8	26
58	Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug. <i>Molecular Pharmaceutics</i> , 2015, 12, 1836-1847.	4.6	45
59	Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results. <i>Cancer Research</i> , 2015, 75, CT236-CT236.	0.9	4
60	Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552). <i>Cancer Research</i> , 2015, 75, P5-19-27-P5-19-27.	0.9	3
61	Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer. <i>Oncotarget</i> , 2015, 6, 4274-4285.	1.8	19
62	Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results. <i>Cancer Research</i> , 2015, 75, P5-19-08-P5-19-08.	0.9	1
63	Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus. <i>PLoS ONE</i> , 2014, 9, e98315.	2.5	24
64	In-Vivo Fusion of Human Cancer and Hamster Stromal Cells Permanently Transduces and Transcribes Human DNA. <i>PLoS ONE</i> , 2014, 9, e107927.	2.5	15
65	A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. <i>MAbs</i> , 2014, 6, 381-391.	5.2	34
66	CD74 interferes with the expression of fas receptor on the surface of lymphoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 80.	8.6	15
67	Al ¹⁸ F labeling of peptides and proteins. <i>Journal of Labelled Compounds and Radiopharmaceutics</i> , 2014, 57, 219-223.	1.0	44
68	Preclinical Comparison of Al ¹⁸ F- and ⁶⁸ Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 2050-2056.	5.0	46
69	Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2 Bispecific Antibody Is Enhanced in Combination with Interferon- γ . <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2341-2351.	4.1	19
70	Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer. <i>Cancer Research</i> , 2014, 74, 6216-6223.	0.9	25
71	Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. <i>Haematologica</i> , 2014, 99, 1738-1745.	3.5	25
72	Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris. <i>JAMA Dermatology</i> , 2014, 150, 1331.	4.1	52

#	ARTICLE	IF	CITATIONS
73	Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer. <i>Molecular Cancer</i> , 2014, 13, 53.	19.2	22
74	Al18F Labeling of Affibody Molecules. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1043.1-1043.	5.0	9
75	Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2—Anti-HSG Bispecific Antibody and a ¹⁷⁷ Lu-Labeled Peptide. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 323-329.	1.0	28
76	Differentiation of Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis by PAM4 Immunohistochemistry. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 220-228.	2.5	22
77	SPECT- and Fluorescence Image—Guided Surgery Using a Dual-Labeled Carcinoembryonic Antigen—Targeting Antibody. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1519-1524.	5.0	35
78	Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1593-602.	6.4	33
79	¹⁸ F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1501-1510.	6.4	14
80	Radiopharmaceutical therapy in the era of precision medicine. <i>European Journal of Cancer</i> , 2014, 50, 2360-2363.	2.8	16
81	Abstract CT206: SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results. <i>Cancer Research</i> , 2014, 74, CT206-CT206.	0.9	5
82	Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies. <i>Cancer Research</i> , 2014, 74, CT211-CT211.	0.9	7
83	Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3107-3107.	1.6	4
84	Radiofluorination using aluminum-fluoride (Al18F). <i>EJNMMI Research</i> , 2013, 3, 36.	2.5	98
85	Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. <i>BMC Cancer</i> , 2013, 13, 170.	2.6	27
86	Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. <i>British Journal of Haematology</i> , 2013, 162, 693-701.	2.5	25
87	Prevention of Acute Graft-versus-Host Disease in a Xenogeneic SCID Mouse Model by the Humanized Anti-CD74 Antagonistic Antibody Milatuzumab. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 28-39.	2.0	15
88	Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. <i>Blood</i> , 2013, 122, 3020-3029.	1.4	98
89	⁹⁰ BCR—ABL ¹ molecular remission after ⁹⁰ Y—epratuzumab tetraxetan radioimmunotherapy in ²² CD ⁺ ⁺ ⁺ P ^h ⁺ ⁺ B ⁺ —ALL: proof of principle. <i>European Journal of Haematology</i> , 2013, 91, 552-556.	2.2	19
90	Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. <i>Molecular Cancer</i> , 2013, 12, 143.	19.2	25

#	ARTICLE	IF	CITATIONS
91	Medullary Thyroid Carcinoma. , 2013, , 155-163.		0
92	Antibody-Targeted Therapeutic Radionuclides in the Management of Colorectal Cancer. , 2013, , 207-237.		2
93	Radioimmunotherapy of Pancreatic Adenocarcinoma. , 2013, , 239-255.		0
94	Pretargeting: Advancing the Delivery of Radionuclides. , 2013, , 369-381.		0
95	Optimization of Multivalent Bispecific Antibodies and Immunocytokines with Improved in Vivo Properties. Bioconjugate Chemistry, 2013, 24, 63-71.	3.6	22
96	Imaging integrin $\alpha v \beta 3$ expression in tumors with an ^{18}F -labeled dimeric RGD peptide. Contrast Media and Molecular Imaging, 2013, 8, 238-245.	0.8	36
97	Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1377-1383.	6.4	41
98	PAM4 enzyme immunoassay alone and in combination with CA 19 μ for the detection of pancreatic adenocarcinoma. Cancer, 2013, 119, 522-528.	4.1	38
99	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology, 2013, 52, 1313-1322.	1.9	115
100	Milatumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies. Clinical Cancer Research, 2013, 19, 347-356.	7.0	34
101	Milatumab μ -SN-38 Conjugates for the Treatment of CD74+ Cancers. Molecular Cancer Therapeutics, 2013, 12, 968-978.	4.1	105
102	The Development of Bispecific Hexavalent Antibodies as a Novel Class of DOCK-AND-LOCKTM (DNLTM) Complexes. Antibodies, 2013, 2, 353-370.	2.5	4
103	Phase I, multicentre, dose μ escalation trial of monotherapy with milatumab (humanized) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Journal of Haematology, 2013, 163, 478-486.	2.5	89
104	^{18}F : A New Standard for Radiofluorination. Journal of Nuclear Medicine, 2013, 54, 1170.1-1170.	5.0	6
105	Monoclonal antibodies targeting CD20. MAbs, 2013, 5, 335-336.	5.2	3
106	Interferon- γ 1 Linked to a Stabilized Dimer of Fab Potently Enhances both Antitumor and Antiviral Activities in Targeted Cells. PLoS ONE, 2013, 8, e63940.	2.5	8
107	Preface: Special Issue on Tumor-Stromal Crosstalk in Oncogenesis. Critical Reviews in Oncogenesis, 2013, 18, v-vii.	0.4	0
108	Horizontal Transmission of Malignancy: In-Vivo Fusion of Human Lymphomas with Hamster Stroma Produces Tumors Retaining Human Genes and Lymphoid Pathology. PLoS ONE, 2013, 8, e55324.	2.5	18

#	ARTICLE	IF	CITATIONS
109	Medullary Thyroid Carcinoma. <i>Medical Radiology</i> , 2012, , 315-321.	0.1	0
110	Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1185-1192.	5.0	74
111	Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1926-1932.	5.0	12
112	Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time. <i>Journal of Clinical Oncology</i> , 2012, 30, 2165-2165.	1.6	8
113	Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. <i>Medical Radiology</i> , 2012, , 551-556.	0.1	1
114	Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. <i>Blood</i> , 2012, 119, 3767-3778.	1.4	43
115	A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2-Expressing Epithelial Cancers. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1625-1632.	5.0	35
116	PET of Tumors Expressing Gastrin-Releasing Peptide Receptor with an ¹⁸ F-Labeled Bombesin Analog. <i>Journal of Nuclear Medicine</i> , 2012, 53, 947-952.	5.0	65
117	New Lyophilized Kit for Rapid Radiofluorination of Peptides. <i>Bioconjugate Chemistry</i> , 2012, 23, 538-547.	3.6	77
118	Epratuzumab- ¹²⁵ I-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 224-234.	4.1	62
119	Designing immunoconjugates for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 873-890.	3.1	45
120	Radioimmunotherapy of Tumors: Pretargeting with Bispecific Antibodies. <i>Medical Radiology</i> , 2012, , 607-615.	0.1	0
121	Antibodies for Nuclear Medicine Therapy. <i>Medical Radiology</i> , 2012, , 125-138.	0.1	0
122	The Dock-and-Lock Method Combines Recombinant Engineering with Site-Specific Covalent Conjugation To Generate Multifunctional Structures. <i>Bioconjugate Chemistry</i> , 2012, 23, 309-323.	3.6	43
123	Complex and defined biostructures with the dock-and-lock method. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 474-481.	8.7	15
124	The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. <i>Arthritis Research and Therapy</i> , 2012, 14, R54.	3.5	30
125	A Novel Class of Anti-HIV Agents with Multiple Copies of Enfuvirtide Enhances Inhibition of Viral Replication and Cellular Transmission In Vitro. <i>PLoS ONE</i> , 2012, 7, e41235.	2.5	15
126	Pretargeted Molecular Imaging and Radioimmunotherapy. <i>Theranostics</i> , 2012, 2, 523-540.	10.0	86

#	ARTICLE	IF	CITATIONS
127	Horizontal transmission of malignancy by cell-cell fusion. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, S133-S139.	3.1	29
128	Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells <i>in vivo</i> . <i>International Journal of Cancer</i> , 2012, 131, 49-58.	5.1	36
129	Using antibodies to target cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1173-1190.	3.1	19
130	Fractionated radioimmunotherapy with ⁹⁰ Y-ivabuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer. <i>Cancer</i> , 2012, 118, 5497-5506.	4.1	79
131	Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). <i>Tumor Biology</i> , 2012, 33, 601-606.	1.8	14
132	Pretargeting: taking an alternate route for localizing radionuclides. <i>Tumor Biology</i> , 2012, 33, 591-600.	1.8	28
133	Introduction to this special issue on tumor targeting. <i>Tumor Biology</i> , 2012, 33, 571-572.	1.8	0
134	The radiolabeling of proteins by the [18F]AlF method. <i>Applied Radiation and Isotopes</i> , 2012, 70, 200-204.	1.5	53
135	Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. <i>EJNMMI Research</i> , 2012, 2, 5.	2.5	22
136	Optimized labeling of NOTA-conjugated octreotide with F-18. <i>Tumor Biology</i> , 2012, 33, 427-434.	1.8	72
137	Evaluation of a Novel Hexavalent Humanized Anti-IGF-1R Antibody and Its Bivalent Parental IgG in Diverse Cancer Cell Lines. <i>PLoS ONE</i> , 2012, 7, e44235.	2.5	8
138	In vitro autoradiography of carcinoembryonic antigen in tissue from patients with colorectal cancer using multifunctional antibody TF2 and (67/68Ga)-labeled haptens by pretargeting. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 141-50.	1.0	13
139	High-Yielding Aqueous ¹⁸ F-Labeling of Peptides via Al ¹⁸ F Chelation. <i>Bioconjugate Chemistry</i> , 2011, 22, 1793-1803.	3.6	137
140	Optimization of Hapten-Peptide Labeling for Pretargeted ImmunoPET of Bispecific Antibody Using Generator-Produced ⁶⁸ Ga. <i>Journal of Nuclear Medicine</i> , 2011, 52, 555-559.	5.0	22
141	Recent progress in cancer therapy with radiolabeled monoclonal antibodies. <i>Therapeutic Delivery</i> , 2011, 2, 675-679.	2.2	5
142	Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. <i>Blood</i> , 2011, 117, 4530-4541.	1.4	75
143	Preclinical studies on targeted delivery of multiple IFN γ 2b to HLA-DR in diverse hematologic cancers. <i>Blood</i> , 2011, 118, 1877-1884.	1.4	33
144	FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. <i>Blood</i> , 2011, 118, 6893-6903.	1.4	46

#	ARTICLE	IF	CITATIONS
145	Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2153-2164.	6.4	25
146	A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines. <i>Biotechnology Progress</i> , 2011, 27, 766-775.	2.6	11
147	Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1601-1607.	5.0	29
148	Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1072-1081.	4.1	44
149	Subcutaneous injections of low-dose velutuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. <i>Haematologica</i> , 2011, 96, 567-573.	3.5	47
150	Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial. <i>Clinical Cancer Research</i> , 2011, 17, 4091-4100.	7.0	60
151	Cancer radioimmunotherapy. <i>Immunotherapy</i> , 2011, 3, 349-370.	2.0	108
152	Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys. <i>Clinical Cancer Research</i> , 2011, 17, 3157-3169.	7.0	213
153	Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 273-284.	1.3	16
154	Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. <i>Blood</i> , 2010, 115, 5180-5190.	1.4	43
155	Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. <i>Blood</i> , 2010, 116, 2554-2558.	1.4	40
156	Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. <i>Blood</i> , 2010, 116, 3258-3267.	1.4	36
157	Introduction to the supplement, "Cancer Therapy with Antibodies and Immunoconjugates". <i>Cancer</i> , 2010, 116, 1011-1012.	4.1	0
158	Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. <i>Cancer</i> , 2010, 116, 1093-1100.	4.1	33
159	Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-ethylenetriaminepentaacetic acid F(ab') ₂ antibody. <i>Cancer</i> , 2010, 116, 1111-1117.	4.1	20
160	Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. <i>Cancer</i> , 2010, 116, 1118-1125.	4.1	19
161	Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides. <i>Cancer</i> , 2010, 116, 1134-1145.	4.1	21
162	New Antibody Conjugates in Cancer Therapy. <i>Scientific World Journal</i> , The, 2010, 10, 2070-2089.	2.1	42

#	ARTICLE	IF	CITATIONS
163	High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3709-3716.	1.6	106
164	Detection of Early-Stage Pancreatic Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2786-2794.	2.5	45
165	Pretargeted Immuno- α Positron Emission Tomography Imaging of Carcinoembryonic Antigen- α Expressing Tumors with a Bispecific Antibody and a ^{68}Ga - and ^{18}F -Labeled Hapten Peptide in Mice with Human Tumor Xenografts. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1019-1027.	4.1	85
166	Pretargeted ^{177}Lu Radioimmunotherapy of Carcinoembryonic Antigen- α Expressing Human Colonic Tumors in Mice. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1780-1787.	5.0	49
167	Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using ^{124}I -IMP-R4 α -Labeled Antibody ch806. <i>Journal of Nuclear Medicine</i> , 2010, 51, 967-972.	5.0	26
168	Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. <i>Leukemia and Lymphoma</i> , 2010, 51, 747-755.	1.3	52
169	Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti- α Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2276-2286.	4.1	48
170	TAp63 Regulates VLA-4 Expression and Chronic Lymphocytic Leukemia Cell Migration to the Bone Marrow in a CD74-Dependent Manner. <i>Journal of Immunology</i> , 2010, 184, 4761-4769.	0.8	53
171	A Novel Facile Method of Labeling Octreotide with ^{18}F -Fluorine. <i>Journal of Nuclear Medicine</i> , 2010, 51, 454-461.	5.0	193
172	Radioactive Antibodies: A Historical Review of Selective Targeting and Treatment of Cancer. <i>Hospital Practice (1995)</i> , 2010, 38, 82-93.	1.0	9
173	A Bispecific Antibody-IFN γ 2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells. <i>Cancer Research</i> , 2010, 70, 7600-7609.	0.9	41
174	Improved Cancer Therapy and Molecular Imaging with Multivalent, Multispecific Antibodies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 1-12.	1.0	19
175	Improved ^{18}F Labeling of Peptides with a Fluoride-Aluminum-Chelate Complex. <i>Bioconjugate Chemistry</i> , 2010, 21, 1331-1340.	3.6	178
176	Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy. <i>Seminars in Nuclear Medicine</i> , 2010, 40, 190-203.	4.6	70
177	Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 12, R204.	3.5	86
178	New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 569-583.	2.4	2
179	Immunoconjugate Anticancer Therapeutics. , 2010, , 371-392.		1
180	Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. <i>International Journal of Clinical and Experimental Pathology</i> , 2010, 4, 1-12.	0.5	15

#	ARTICLE	IF	CITATIONS
181	Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines. <i>Clinical Cancer Research</i> , 2009, 15, 2808-2817.	7.0	54
182	Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results. <i>Journal of Clinical Oncology</i> , 2009, 27, 3346-3353.	1.6	154
183	Induction of Apoptosis by Cross-Linking Antibodies Bound to Human B-Lymphoma Cells: Expression of Annexin V Binding Sites on the Antibody Cap. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 185-193.	1.0	9
184	CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates. <i>Clinical Cancer Research</i> , 2009, 15, 6052-6061.	7.0	105
185	Advances and challenges in developing cytokine fusion proteins as improved therapeutics. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 181-194.	5.0	13
186	Ceramide Regulates Gemcitabine-Induced Senescence and Apoptosis in Human Pancreatic Cancer Cell Lines. <i>Molecular Cancer Research</i> , 2009, 7, 890-896.	3.4	54
187	A Novel Method of ¹⁸ F Radiolabeling for PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 991-998.	5.0	349
188	Pretargeted Radioimmunotherapy of Pancreatic Cancer Xenografts: TF10 ⁹⁰ Y-IMP-288 Alone and Combined with Gemcitabine. <i>Journal of Nuclear Medicine</i> , 2009, 50, 2008-2016.	5.0	50
189	A New Method to Produce MonoPEGylated Dimeric Cytokines Shown with Human Interferon- β . <i>Bioconjugate Chemistry</i> , 2009, 20, 1899-1907.	3.6	19
190	Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2009, 50, 444-453.	5.0	57
191	A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. <i>Blood</i> , 2009, 113, 3891-3895.	1.4	62
192	Novel strategies for improved cancer vaccines. <i>Expert Review of Vaccines</i> , 2009, 8, 567-576.	4.4	19
193	Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. <i>Blood</i> , 2009, 113, 1062-1070.	1.4	115
194	Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. <i>Blood</i> , 2009, 113, 6161-6171.	1.4	68
195	Some like it hot: lymphoma radioimmunotherapy. <i>Blood</i> , 2009, 113, 4823-4824.	1.4	2
196	CD20-targeted tetrameric interferon- β , a novel and potent immunocytokine for the therapy of B-cell lymphomas. <i>Blood</i> , 2009, 114, 3864-3871.	1.4	59
197	Therapy of human carcinoma xenografts with antibodies to EGFR and HER-2 conjugated to radionuclides emitting low-energy electrons. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1249-1258.	6.4	10
198	Durable complete responses from therapy with combined epratuzumab and rituximab. <i>Cancer</i> , 2008, 113, 2714-2723.	4.1	102

#	ARTICLE	IF	CITATIONS
199	Use of antibodies and immunoconjugates for the therapy of more accessible cancers. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 1407-1420.	13.7	54
200	Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6916-6926.	6.4	115
201	Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab). <i>Clinical Cancer Research</i> , 2008, 14, 6154-6160.	7.0	45
202	Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 3756-3762.	1.6	211
203	A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma. <i>Cancer Research</i> , 2008, 68, 4819-4826.	0.9	69
204	Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting. <i>Journal of Nuclear Medicine</i> , 2008, 49, 158-163.	5.0	134
205	Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody. <i>Cancer Research</i> , 2008, 68, 5282-5290.	0.9	71
206	Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics. <i>Cancer Research</i> , 2008, 68, 8384-8392.	0.9	59
207	Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model. <i>Radiology</i> , 2008, 246, 497-507.	7.3	55
208	Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. <i>Haematologica</i> , 2008, 93, 390-397.	3.5	45
209	Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. <i>Blood</i> , 2008, 111, 2211-2219.	1.4	52
210	Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types. <i>PPAR Research</i> , 2008, 2008, 1-7.	2.4	60
211	Novel radioimmunopharmaceuticals for cancer imaging and therapy. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 1302-16.	2.3	15
212	CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms. <i>Clinical Cancer Research</i> , 2007, 13, 5556s-5563s.	7.0	188
213	IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13408-13413.	7.1	162
214	A Divalent Hapten-Peptide Induces Apoptosis in Human Non-Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 and Anti-Hapten Bispecific Antibodies. <i>Clinical Cancer Research</i> , 2007, 13, 5564s-5571s.	7.0	2
215	Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4590-4597.	3.6	89
216	The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity. <i>Clinical Cancer Research</i> , 2007, 13, 5586s-5591s.	7.0	68

#	ARTICLE	IF	CITATIONS
217	Bispecific Antibody Pretargeting of Radionuclides for Immuno- ⁶⁷ Single-Photon Emission Computed Tomography and Immuno- ⁶⁷ Positron Emission Tomography Molecular Imaging: An Update. <i>Clinical Cancer Research</i> , 2007, 13, 5577s-5585s.	7.0	36
218	Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 524-531.	4.1	66
219	PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 7380-7387.	7.0	85
220	Cancer imaging and therapy with bispecific antibody pretargeting. <i>Update on Cancer Therapeutics</i> , 2007, 2, 19-31.	0.4	82
221	Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. <i>Molecular Immunology</i> , 2007, 44, 1331-1341.	2.2	176
222	Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. <i>BMC Cancer</i> , 2007, 7, 2.	2.6	192
223	Update of Carcinoembryonic Antigen Radioimmunotherapy with ¹³¹ I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group. <i>Annals of Surgical Oncology</i> , 2007, 14, 2577-2590.	1.5	74
224	Methods and goals for the use of in vitro and in vivo chemosensitivity testing. <i>Molecular Biotechnology</i> , 2007, 35, 185-197.	2.4	60
225	Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2007, 110, 3419-3419.	1.4	1
226	Targeting CD22 as a strategy for treating systemic autoimmune diseases. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 953-9.	2.0	28
227	Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. <i>Arthritis Research and Therapy</i> , 2006, 8, R129.	3.5	212
228	Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006, 8, R74.	3.5	267
229	Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. <i>Blood</i> , 2006, 108, 2736-2744.	1.4	50
230	Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. <i>Aids</i> , 2006, 20, 1911-1915.	2.2	16
231	Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 47-55.	4.2	8
232	Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. <i>Ca-A Cancer Journal for Clinicians</i> , 2006, 56, 226-243.	329.8	207
233	B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: Comment on the editorial by St.Clair and Tedder. <i>Arthritis and Rheumatism</i> , 2006, 54, 2344-2344.	6.7	4
234	Advances in Radioimmunotherapy in the Age of Molecular Engineering and Pretargeting. <i>Cancer Investigation</i> , 2006, 24, 82-97.	1.3	31

#	ARTICLE	IF	CITATIONS
235	Sphingolipid targets in cancer therapy. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 200-208.	4.1	125
236	Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti- α -Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 1705-1711.	1.6	231
237	New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis. <i>Journal of Clinical Oncology</i> , 2006, 24, 252-258.	1.6	126
238	Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 5587-5595.	7.0	36
239	Epratuzumab in the therapy of oncological and immunological diseases. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1341-1353.	2.4	54
240	Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3880-3886.	1.6	148
241	Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 823-834.	1.6	327
242	Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6841-6846.	7.1	196
243	Multivalent Anti-CD20/Anti-CD22 Bispecific Antibody Fusion Proteins Made by the DNL Method Show Potent Lymphoma Cytotoxicity. <i>Blood</i> , 2006, 108, 2495-2495.	1.4	2
244	Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results. <i>Blood</i> , 2006, 108, 2719-2719.	1.4	7
245	Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and ^{131}I -labeled bivalent hapten in a phase I optimization clinical trial. <i>Journal of Nuclear Medicine</i> , 2006, 47, 247-55.	5.0	88
246	Bispecific antibody pretargeting PET (immunoPET) with an ^{124}I -labeled hapten-peptide. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1678-88.	5.0	81
247	Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. <i>Blood</i> , 2005, 106, 4308-4314.	1.4	53
248	Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. <i>Nature Medicine</i> , 2005, 11, 1250-1255.	30.7	144
249	Comparison of IgG and F(ab α) 2 fragments of bispecific anti-RCC α -anti-DTln-1 antibody for pretargeting purposes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1089-1095.	6.4	9
250	Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 901-909.	6.4	18
251	Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 315-327.	4.2	48
252	Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy With ^{131}I -Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results. <i>Journal of Clinical Oncology</i> , 2005, 23, 6763-6770.	1.6	126

#	ARTICLE	IF	CITATIONS
253	Inhibition of Adhesion, Invasion, and Metastasis by Antibodies Targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). <i>Cancer Research</i> , 2005, 65, 8809-8817.	0.9	184
254	Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft. <i>Clinical Cancer Research</i> , 2005, 11, 7879-7885.	7.0	58
255	Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies. <i>Technology in Cancer Research and Treatment</i> , 2005, 4, 375-391.	1.9	35
256	Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2005, 11, 2727-2734.	7.0	19
257	Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. <i>Expert Review of Clinical Immunology</i> , 2005, 1, 47-62.	3.0	32
258	Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods. <i>Clinical Cancer Research</i> , 2005, 11, 7109s-7121s.	7.0	111
259	Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys. <i>Clinical Cancer Research</i> , 2005, 11, 5257-5264.	7.0	162
260	Pretargeting of Carcinoembryonic Antigen-Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells. <i>Clinical Cancer Research</i> , 2005, 11, 7122s-7129s.	7.0	46
261	Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab. <i>Clinical Cancer Research</i> , 2005, 11, 5215-5222.	7.0	109
262	Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5044-5051.	1.6	164
263	Pretargeting of Carcinoembryonic Antigen-Expressing Tumors with a Biologically Produced Bispecific Anticarcinoembryonic Antigen - Anti-Indium-111 Labeled Diethylenetriaminepentaacetic Acid Antibody. <i>Clinical Cancer Research</i> , 2005, 11, 7130s-7136s.	7.0	15
264	Development of humanized antibodies as cancer therapeutics. <i>Methods</i> , 2005, 36, 84-95.	3.8	46
265	¹⁷⁷ Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. <i>Nuclear Medicine and Biology</i> , 2005, 32, 269-278.	0.6	40
266	Deferoxamine as a chelator for ⁶⁷ Ga in the preparation of antibody conjugates. <i>Nuclear Medicine and Biology</i> , 2005, 32, 513-519.	0.6	30
267	Perspectives on cancer therapy with radiolabeled monoclonal antibodies. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 115S-27S.	5.0	48
268	Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. <i>Clinical Cancer Research</i> , 2005, 11, 777-86.	7.0	22
269	A phase I trial combining high-dose ⁹⁰ Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. <i>Journal of Nuclear Medicine</i> , 2005, 46, 620-33.	5.0	42
270	Synergistic Interaction between Sphingomyelin and Gemcitabine Potentiates Ceramide-Mediated Apoptosis in Pancreatic Cancer. <i>Cancer Research</i> , 2004, 64, 8405-8410.	0.9	62

#	ARTICLE	IF	CITATIONS
271	Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2004, 10, 5327-5334.	7.0	221
272	CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy. <i>Clinical Cancer Research</i> , 2004, 10, 6606-6611.	7.0	140
273	Improved Targeting of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 3552-3561.	7.0	29
274	Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2004, 10, 2868-2878.	7.0	168
275	Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel. <i>Breast Cancer Research and Treatment</i> , 2004, 84, 173-182.	2.5	44
276	An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression. <i>International Journal of Cancer</i> , 2004, 108, 293-300.	5.1	15
277	Diagnosing suspected acute nonclassic appendicitis with sulesomab, a radiolabeled antigranulocyte antibody imaging agent. <i>Journal of Pediatric Surgery</i> , 2004, 39, 1338-1344.	1.6	12
278	Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. <i>Blood</i> , 2004, 104, 3705-3711.	1.4	126
279	Construction and Characterization of a Novel Ribonuclease Immunotoxin Consisting of Two Ranpirnase (Rap) Molecules Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody. <i>Blood</i> , 2004, 104, 3289-3289.	1.4	1
280	Reagents and methods for PET using bispecific antibody pretargeting and ⁶⁸ Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. <i>Journal of Nuclear Medicine</i> , 2004, 45, 30-9.	5.0	43
281	Biodistribution and therapeutic efficacy of (¹²⁵ I)-, (¹⁸⁶ Re)-, (⁸⁸ Y)-, or (¹⁷⁷ Lu)-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1224-32.	5.0	53
282	A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1559-64.	4.1	22
283	Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 777-780.	6.4	39
284	Advancing role of radiolabeled antibodies in the therapy of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 281-296.	4.2	92
285	CD22-directed monoclonal antibody therapy for lymphoma. <i>Seminars in Oncology</i> , 2003, 30, 457-464.	2.2	27
286	Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: Potential relationship to posttherapy tumor angiogenesis and recurrence. <i>International Journal of Cancer</i> , 2003, 105, 158-164.	5.1	54
287	Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. <i>International Journal of Cancer</i> , 2003, 106, 965-972.	5.1	34
288	Use of Ibritumomab Tiuxetan Anti-CD20 Radioimmunotherapy in a Non-Hodgkin's Lymphoma Patient Previously Treated with a Yttrium-90 Labeled Anti-CD22 Monoclonal Antibody. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 56-59.	2.1	11

#	ARTICLE	IF	CITATIONS
289	Experimental therapy of disseminated B-Cell lymphoma xenografts with ²¹³ Bi-labeled anti-CD74. <i>Nuclear Medicine and Biology</i> , 2003, 30, 715-723.	0.6	18
290	Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3051-3059.	1.6	245
291	Biodistribution of ¹³¹ I-, ¹⁸⁶ Re-, ¹⁷⁷ Lu-, and ⁸⁸ Y-Labeled hLL2 (Epratuzumab) in Nude Mice with CD22-Positive Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 525-533.	1.0	25
292	Tumor pO ₂ Assessments in Human Xenograft Tumors Measured by EPR Oximetry: Location of Paramagnetic Materials. <i>Advances in Experimental Medicine and Biology</i> , 2003, 530, 205-214.	1.6	0
293	Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. <i>Journal of Nuclear Medicine</i> , 2003, 44, 67-76.	5.0	35
294	⁹⁰ Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. <i>Journal of Nuclear Medicine</i> , 2003, 44, 77-84.	5.0	54
295	Improved iodine radiolabels for monoclonal antibody therapy. <i>Cancer Research</i> , 2003, 63, 111-8.	0.9	49
296	A universal pretargeting system for cancer detection and therapy using bispecific antibody. <i>Cancer Research</i> , 2003, 63, 354-63.	0.9	75
297	Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. <i>Clinical Cancer Research</i> , 2003, 9, 3886S-96S.	7.0	30
298	Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. <i>Clinical Cancer Research</i> , 2003, 9, 3897S-913S.	7.0	35
299	Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. <i>Clinical Cancer Research</i> , 2003, 9, 3973S-81S.	7.0	37
300	Epratuzumab: targeting B-cell malignancies through CD22. <i>Clinical Cancer Research</i> , 2003, 9, 3991S-4S.	7.0	34
301	Radioimmunotherapy of non-Hodgkin's lymphoma with ⁹⁰ Y-DOTA humanized anti-CD22 IgG (⁹⁰ Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?. <i>Journal of Nuclear Medicine</i> , 2003, 44, 2000-18.	5.0	62
302	Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. <i>Clinical Cancer Research</i> , 2003, 9, 6567-71.	7.0	61
303	Specifically Targeting the CD22 Receptor of Human B-cell Lymphomas with RNA Damaging Agents: A New Generation of Therapeutics. <i>Leukemia and Lymphoma</i> , 2002, 43, 953-959.	1.3	35
304	Use of Galactosylated-Streptavidin as a Clearing Agent with ¹¹¹ In-Labeled, Biotinylated Antibodies to Enhance Tumor/Non-Tumor Localization Ratios. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 307-316.	1.0	7
305	Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma. <i>Cancer</i> , 2002, 94, 51-61.	4.1	30
306	Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. <i>Cancer</i> , 2002, 94, 1373-1381.	4.1	94

#	ARTICLE	IF	CITATIONS
307	Phase I Radioimmunotherapy Trial with Iodine-131 ¹²⁵ I Labeled Humanized MN-14 Anti ¹²⁵ I Carcinoembryonic Antigen Monoclonal Antibody in Patients with Metastatic Gastrointestinal and Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2002, 2, 31-42.	2.3	49
308	Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. <i>International Journal of Oncology</i> , 2002, 20, 379-84.	3.3	9
309	Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. <i>Clinical Cancer Research</i> , 2002, 8, 1213-22.	7.0	19
310	Targeted therapy of cancer with radiolabeled antibodies. <i>Journal of Nuclear Medicine</i> , 2002, 43, 693-713.	5.0	197
311	Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 553-63.	4.1	96
312	Potent and specific antitumor effects of an anti-CD22 ¹²⁵ I targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. <i>Blood</i> , 2001, 97, 528-535.	1.4	109
313	Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 173-180.	4.4	10
314	The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 195-201.	4.4	85
315	Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 147-154.	4.4	33
316	Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 79-86.	4.4	17
317	Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. <i>International Journal of Cancer</i> , 2001, 94, 564-571.	5.1	18
318	Unique molecular markers in human endometriosis: implications for diagnosis and therapy. <i>Expert Reviews in Molecular Medicine</i> , 2001, 3, 1-12.	3.9	4
319	Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. <i>Cancer</i> , 2000, 88, 333-343.	4.1	34
320	Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy. , 2000, 86, 276-280.		45
321	Achievement of high cell density and high antibody productivity by a controlled-fed perfusion bioreactor process. , 2000, 69, 74-82.		42
322	Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. <i>Cancer</i> , 2000, 89, 104-115.	4.1	14
323	Advances in the use of monoclonal antibodies in cancer radiotherapy. <i>Pharmaceutical Science & Technology Today</i> , 2000, 3, 90-98.	0.7	13
324	Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival?11Dr Goldenberg is a member of the board of Immunomedics and a shareholder. Immunomedics markets CEA-Scan (arcitumomab).. <i>Journal of the American College of Surgeons</i> , 2000, 191, 511-518.	0.5	28

#	ARTICLE	IF	CITATIONS
325	CEA Immunoscintigraphy Detects Resectable Rectal Cancer Recurrence and Improves Survival. <i>Coloproctology</i> , 2000, 22, 23-28.	0.3	1
326	Sphingomyelin Potentiates Chemotherapy of Human Cancer Xenografts. <i>Biochemical and Biophysical Research Communications</i> , 2000, 268, 603-606.	2.1	27
327	Degranulating Eosinophils in Human Endometriosis. <i>American Journal of Pathology</i> , 2000, 156, 1581-1588.	3.8	51
328	Co-Secretion of Two Distinct Kappa Light Chains by the Mu-9 Hybridoma. <i>Hybridoma</i> , 1999, 18, 325-333.	0.6	4
329	Phase I/II trial of 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. , 1999, 85, 1828-1842.		73
330	Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. , 1999, 81, 985-992.		47
331	Carcinoembryonic Antigen as a Target for Radioimmunotherapy of Human Medullary Thyroid Carcinoma: Antibody Processing, Targeting, and Experimental Therapy with 131I and 90Y Labeled MAbs. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1999, 14, 37-47.	1.0	19
332	Rapid diagnostic imaging of acute, nonclassic appendicitis by leukoscintigraphy with sulesomab, a technetium 99mâ€“labeled antigranulocyte antibody Fabâ€² fragment. <i>Surgery</i> , 1999, 125, 288-296.	1.9	45
333	Labeling of Monoclonal Antibodies with Diethylenetriaminepentaacetic Acid-Appended Radioiodinated Peptides Containing<sc>d</sc>-Amino Acids. <i>Bioconjugate Chemistry</i> , 1999, 10, 231-240.	3.6	33
334	Breast cancer imaging with radiolabeled antibodies. <i>Seminars in Nuclear Medicine</i> , 1999, 29, 41-48.	4.6	42
335	Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates. <i>Journal of Immunological Methods</i> , 1998, 213, 131-144.	1.4	18
336	Therapeutic efficacy and dose-limiting toxicity of auger-electronvs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of 125I-vs.131I-labeled CO17-1A in a human colorectal cancer model. , 1998, 76, 738-748.		45
337	Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. , 1998, 77, 787-795.		44
338	90Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy: A Radiolabeling and Animal Biodistribution Studiesâ€. <i>Bioconjugate Chemistry</i> , 1998, 9, 773-782.	3.6	26
339	Radioimmunotherapy of Solid Tumors: A Review "Of Mice and Men". <i>Hybridoma</i> , 1997, 16, 101-107.	0.6	33
340	Development of a Streptavidinâ”Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. <i>Reagent Developmentâ€. Bioconjugate Chemistry</i> , 1997, 8, 585-594.	3.6	35
341	Development of a Streptavidinâ”Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. <i>Studies in a Human Colon Cancer Xenograft Modelâ€. Bioconjugate Chemistry</i> , 1997, 8, 595-604.	3.6	50
342	Changes in Tumor Vascular Permeability in Response to Experimental Radioimmunotherapy: A Comparative Study of 11 Xenografts. <i>Tumor Biology</i> , 1997, 18, 367-377.	1.8	16

#	ARTICLE	IF	CITATIONS
343	Prospects of Radioimmunotherapy in Epithelial Ovarian Cancer: Results with Iodine-131-Labeled Murine and Humanized MN-14 Anti-carcinoembryonic Antigen Monoclonal Antibodies. <i>Gynecologic Oncology</i> , 1997, 67, 259-271.	1.4	41
344	Perspectives on oncologic imaging with radiolabeled antibodies. <i>Cancer</i> , 1997, 80, 2431-2435.	4.1	35
345	Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates. <i>Cancer</i> , 1997, 80, 2591-2610.	4.1	98
346	Defining the optimal spacing between repeat radioantibody doses in experimental models. <i>Cancer</i> , 1997, 80, 2624-2635.	4.1	4
347	Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. <i>Cancer</i> , 1997, 80, 2636-2641.	4.1	28
348	Can occult metastases be Treated by radioimmunotherapy?. <i>Cancer</i> , 1997, 80, 2656-2659.	4.1	10
349	Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2). <i>Cancer</i> , 1997, 80, 2660-2666.	4.1	13
350	Chimerization of mu-9. <i>Cancer</i> , 1997, 80, 2667-2674.	4.1	7
351	Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies. <i>Cancer</i> , 1997, 80, 2749-2753.	4.1	7
352	Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice. , 1997, 70, 323-329.		4
353	The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody. , 1997, 71, 429-435.		22
354	Application of cytokine intervention for improved radio-antibody dose delivery. , 1997, 72, 166-173.		5
355	Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. , 1997, 72, 477-485.		45
356	Use of Carcinoembryonic Antigen Radioimmunodetection and Computed Tomography for Predicting the Resectability of Recurrent Colorectal Cancer. <i>Annals of Surgery</i> , 1997, 226, 621-631.	4.2	45
357	Thiolations, 99mTc Labelings, and Animal In Vivo Biodistributions of Divalent Monoclonal Antibody Fragments. <i>Bioconjugate Chemistry</i> , 1996, 7, 290-297.	3.6	5
358	Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. <i>Biochemical Journal</i> , 1996, 320, 293-300.	3.7	80
359	Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2. , 1996, 78, 157-168.		21
360	Rapid Imaging of Infections With a Monoclonal Antibody Fragment (LeukoScan). <i>Clinical Orthopaedics and Related Research</i> , 1996, 329, 263-272.	1.5	80

#	ARTICLE	IF	CITATIONS
361	Carcinoembryonic Antigen as a Target Cancer Antigen for Radiolabeled Antibodies: Prospects for Cancer Imaging and Therapy. <i>Tumor Biology</i> , 1995, 16, 62-73.	1.8	20
362	Effect of VK framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site. <i>International Journal of Cancer</i> , 1995, 60, 534-538.	5.1	14
363	Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. <i>International Journal of Cancer</i> , 1995, 61, 557-566.	5.1	26
364	The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7 ^{3G11} , is phosphorylated on serine 303. <i>International Journal of Cancer</i> , 1995, 62, 472-479.	5.1	74
365	Clinical Utility of Radioimmunoscintigraphy of Non-Hodgkin's Lymphoma with Radiolabelled LL2 Monoclonal Antibody., <i>Lymphoscans</i> , Φ : Preliminary Results. <i>Tumori</i> , 1995, 81, 173-178.	1.1	5
366	Tumor targeting and pharmacokinetics of unmodified and modified F(ab) ₂ fragments of an anti-CEA murine monoclonal antibody (Immu-14). <i>Nuclear Medicine and Biology</i> , 1995, 22, 425-435.	0.6	4
367	Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. <i>Molecular Immunology</i> , 1995, 32, 1413-1427.	2.2	96
368	Internalization of an intact doxorubicin immunoconjugate. <i>Cancer Immunology, Immunotherapy</i> , 1994, 38, 92-98.	4.2	42
369	Cytokine Intervention permits dose escalation of radioantibody. An analysis of myelostimulation by bolus versus continuous infusion of IL-1/GM-CSF. <i>Cancer</i> , 1994, 73, 1083-1092.	4.1	13
370	Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies. <i>Cancer</i> , 1994, 73, 761-768.	4.1	37
371	Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. <i>Cancer</i> , 1994, 73, 787-793.	4.1	82
372	Comparative biodistribution and radioimmunotherapy of monoclonal antibody rs7 and its f(ab ²) ₂ in nude mice bearing human tumor xenografts. <i>Cancer</i> , 1994, 73, 816-823.	4.1	16
373	Phase I clinical evaluation of a new murine monoclonal antibody (mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas. <i>Cancer</i> , 1994, 73, 864-877.	4.1	20
374	Internalization and intracellular processing of an anti B-cell lymphoma monoclonal antibody, ll2. <i>International Journal of Cancer</i> , 1994, 56, 538-545.	5.1	70
375	Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti-idiotypic antibody. <i>International Journal of Cancer</i> , 1994, 56, 580-584.	5.1	23
376	Characterization of cluster 13: The epithelial/carcinoma antigen recognized by MAb RS7. <i>International Journal of Cancer</i> , 1994, 57, 98-102.	5.1	53
377	The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. <i>Seminars in Nuclear Medicine</i> , 1994, 24, 142-153.	4.6	127
378	Normal colonic epithelium adheres to carcinoembryonic antigen and type IV collagen. <i>Gastroenterology</i> , 1994, 106, 1242-1250.	1.3	36

#	ARTICLE	IF	CITATIONS
379	Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. <i>Cancer</i> , 1993, 71, 2082-2096.	4.1	53
380	Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. <i>Cancer</i> , 1993, 71, 3478-3485.	4.1	68
381	Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. <i>International Journal of Cancer</i> , 1993, 55, 938-946.	5.1	75
382	Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. <i>Cancer Immunology, Immunotherapy</i> , 1993, 37, 293-298.	4.2	70
383	Monoclonal antibodies in cancer detection and therapy. <i>American Journal of Medicine</i> , 1993, 94, 297-312.	1.5	133
384	Microheterogeneity of a purified IgG1, due to asymmetric fab glycosylation. <i>Molecular Immunology</i> , 1992, 29, 751-758.	2.2	26
385	Localization by whole-body autoradiography of intact and fragmented radiolabeled antibodies in a metastatic human colonic cancer model. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1992, 19, 87-99.	0.3	6
386	Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. <i>Bioconjugate Chemistry</i> , 1992, 3, 91-99.	3.6	67
387	Endobronchial Deposition of Radioactive Monoclonal Antibody in Patients with Inoperable Non-Small-Cell Carcinoma of the Lung. <i>Chest</i> , 1992, 102, 1633-1634.	0.8	0
388	Lymphoma imaging with a new technetium-99m labelled antibody, LL2. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1992, 19, 394-401.	2.1	27
389	Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor. <i>Cancer Immunology, Immunotherapy</i> , 1992, 35, 127-134.	4.2	19
390	Haematological effects of radioimmunotherapy in cancer patients. <i>British Journal of Haematology</i> , 1992, 80, 69-76.	2.5	10
391	Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti-idiotypic antibody in tumor-bearing nude mice. <i>International Journal of Cancer</i> , 1992, 51, 266-273.	5.1	27
392	Physiological factors influencing radioantibody uptake: A study of four human colonic carcinomas. <i>International Journal of Cancer</i> , 1992, 51, 935-941.	5.1	14
393	Conjugation of phenyl isothiocyanate derivatives of carborane to antitumor antibody and in vivo localization of conjugates in nude mice. <i>Bioconjugate Chemistry</i> , 1991, 2, 102-110.	3.6	52
394	Prospects for the Management of Non-Small-Cell Carcinoma of the Lung with Monoclonal Antibodies. <i>Chest</i> , 1991, 99, 1466-1476.	0.8	16
395	SPECT Anti-CEA Monoclonal Antibody Detection of Occult Colorectal Carcinoma Metastases. <i>Clinical Nuclear Medicine</i> , 1991, 16, 849-852.	1.3	16
396	Labeling of monoclonal antibody conjugates with ⁹⁰ Y. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1991, 42, 421-426.	0.5	3

#	ARTICLE	IF	CITATIONS
397	The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: An autoradiographic study. <i>Cancer Immunology, Immunotherapy</i> , 1991, 33, 351-358.	4.2	50
398	Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p. <i>Cancer Immunology, Immunotherapy</i> , 1991, 32, 303-310.	4.2	18
399	Suppression of Tumor Vascular Activity by Radioantibody Therapy: Implications for Multiple Cycle Treatments. <i>Selective Cancer Therapeutics</i> , 1991, 7, 9-16.	0.5	11
400	Cancer Imaging and Therapy with Radiolabeled Antibodies. <i>Advances in Experimental Medicine and Biology</i> , 1991, 303, 107-117.	1.6	3
401	Current perspectives and challenges in the use of monoclonal antibodies as imaging and therapeutic agents. <i>Advanced Drug Delivery Reviews</i> , 1990, 4, 279-318.	13.7	18
402	Effects of methotrexate-carcinoembryonic-antigen-antibody immunoconjugates on GW-39 human tumors in nude mice. <i>Cancer Immunology, Immunotherapy</i> , 1990, 31, 197-201.	4.2	8
403	Selection of a dtpa chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice. <i>International Journal of Cancer</i> , 1990, 46, 79-85.	5.1	30
404	Baboon anti-idiotypic antibodies mimic a carcinoembryonic antigen epitope. <i>International Journal of Cancer</i> , 1990, 46, 310-314.	5.1	14
405	A fluorouridine-anti-CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model. <i>International Journal of Cancer</i> , 1990, 46, 1101-1106.	5.1	16
406	Cancer Imaging with Radiolabeled Antibodies. <i>Frontiers of Radiation Therapy and Oncology</i> , 1990, 24, 90-95.	1.4	9
407	Clinical radioimmunodetection: The second decade. <i>Cancer Treatment and Research</i> , 1990, 51, 3-9.	0.5	1
408	Labeling of anti-tumor antibodies and antibody fragments with Tc-99m. <i>Cancer Treatment and Research</i> , 1990, 51, 233-244.	0.5	7
409	In-vivo antibody imaging for the detection of human tumors. <i>Cancer Treatment and Research</i> , 1990, 51, 273-292.	0.5	9
410	Anti-antibody enhancement of tumor imaging. <i>Cancer Treatment and Research</i> , 1990, 51, 433-455.	0.5	8
411	Experimental model systems for antibody targeting and radioimmunodetection. <i>Cancer Treatment and Research</i> , 1990, 51, 29-52.	0.5	4
412	Comparison of therapeutic efficacy and host toxicity of two different ¹³¹ I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. <i>International Journal of Cancer</i> , 1989, 44, 292-300.	5.1	41
413	Imaging of colorectal carcinoma with radiolabeled antibodies. <i>Seminars in Nuclear Medicine</i> , 1989, 19, 262-281.	4.6	66
414	Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy. <i>Seminars in Nuclear Medicine</i> , 1989, 19, 332-339.	4.6	68

#	ARTICLE	IF	CITATIONS
415	Site-specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier. <i>International Journal of Cancer</i> , 1988, 41, 832-839.	5.1	32
416	Purification and Characterization of Carcinoembryonic Antigen from GW-39, a Xenografted Human Colonic Tumor System. <i>Tumor Biology</i> , 1988, 9, 212-220.	1.8	13
417	Representation of Epitopes on Colon-Specific Antigen-p Defined by Monoclonal Antibodies ref-type="fn" rid="FN2">2. <i>Journal of the National Cancer Institute</i>, 1987, , .	6.3	1
418	Antibody protein dose and radioimmunodetection of gw-39 human colon tumor xenografts. <i>International Journal of Cancer</i> , 1987, 39, 611-617.	5.1	22
419	Current status of cancer imaging with radiolabeled antibodies. <i>Journal of Cancer Research and Clinical Oncology</i> , 1987, 113, 203-208.	2.5	41
420	Preliminary findings in the evaluation of hepatic malignancies by radioimmunodetection, X-ray computed tomography, and magnetic resonance imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1986, 12, 429-435.	2.1	6
421	Diagnosis and treatment of neoplasms with radionuclide-labeled antibodies. <i>Seminars in Nuclear Medicine</i> , 1985, 15, 2-11.	4.6	39
422	Clinical Studies of Prostatic Cancer Imaging with Radiolabeled Antibodies Against Prostatic Acid Phosphatase. <i>Urologic Clinics of North America</i> , 1984, 11, 277-281.	1.8	14
423	Antimarker antibodies for the external imaging of gastrointestinal cancer. <i>Cancer Treatment and Research</i> , 1984, , 351-362.	0.5	2
424	Radioimmunodetection of Prostatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 1983, 250, 630.	7.4	39
425	Carcinoembryonic antigen radioimmunodetection in the evaluation of colorectal cancer and in the detection of occult neoplasms. <i>Gastroenterology</i> , 1983, 84, 524-532.	1.3	106
426	Radioactive antibodies for cancer detection in vivo. <i>Clinical Immunology Newsletter</i> , 1982, 3, 61-64.	0.1	1
427	Colon-specific antigen-p (CSAp). I: Initial clinical evaluation as a marker for colorectal cancer. <i>Cancer</i> , 1982, 50, 919-926.	4.1	15
428	Colon-specific antigen-p (CSAp). II: Further characterization in colorectal and pancreatic cancer. <i>Cancer</i> , 1982, 50, 927-931.	4.1	10
429	Carcinoembryonic Antigen: Its Role as a Marker in the Management of Cancer. A National Institutes of Health Consensus Development Conference. <i>Annals of Internal Medicine</i> , 1981, 94, 407.	3.9	65
430	Immunoperoxidase Localization of Carcinoembryonic Antigen in Normal Human Intestinal Mucosa ref-type="fn" rid="FN2">2 ref-type="fn" rid="FN3">3. <i>Journal of the National Cancer Institute</i>, 1981, , .	6.3	7
431	Experimental studies of tumor radioimmunodetection using antibody mixtures against carcinoembryonic antigen (CEA) and colon-specific antigen-p (CSAp). <i>International Journal of Cancer</i> , 1981, 27, 101-105.	5.1	41
432	Radioimmunodetection of colorectal cancer. <i>Cancer</i> , 1980, 45, 1243-1247.	4.1	25

#	ARTICLE	IF	CITATIONS
433	Clinical studies on the radioimmuno-detection of tumors containing alpha-fetoprotein. <i>Cancer</i> , 1980, 45, 2500-2505.	4.1	122
434	Antigens Associated with Human Solid Tumors. , 1980, , 329-369.		9
435	Alteration in tryptic peptide patterns of ferritins purified from human colon carcinoma. <i>Biochimica Et Biophysica Acta (BBA) - Protein Structure</i> , 1979, 581, 193-197.	1.7	4
436	Introduction to the international conference on the clinical uses of carcinoembryonic antigen. <i>Cancer</i> , 1978, 42, 1397-1398.	4.1	12
437	Immunoperoxidase detection of carcinoembryonic antigen.An overview. <i>Cancer</i> , 1978, 42, 1540-1545.	4.1	29
438	Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens. <i>Cancer</i> , 1978, 42, 1546-1553.	4.1	143
439	Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning. <i>New England Journal of Medicine</i> , 1978, 298, 1384-1388.	27.0	714
440	Immunoperoxidase detection of carcinoembryonic antigen.An overview. <i>Cancer</i> , 1978, 42, 1540-1545.	4.1	19
441	Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens. <i>Cancer</i> , 1978, 42, 1546-1553.	4.1	97
442	Karyology of a human colonic carcinoma (GW-39) serially xenografted in hamsters and in nude mice. <i>Cancer Letters</i> , 1977, 2, 195-200.	7.2	8
443	Characterization and localization of carcinoembryonic antigen in a squamous cell carcinoma of the cervix. <i>Gynecologic Oncology</i> , 1976, 4, 204-211.	1.4	21
444	Carcinoembryonic Antigen in Histopathology: Immunoperoxidase Staining of Conventional Tissue Sections2. <i>Journal of the National Cancer Institute</i> , 1976, 57, 11-22.	6.3	209
445	Oncogenesis by interspecific interaction of malignant murine and non-malignant hamster cells in vitro. <i>International Journal of Cancer</i> , 1975, 15, 282-300.	5.1	7
446	Detection of carcinoembryonic antigen in tissue sections by immunoperoxidase. <i>Journal of Immunological Methods</i> , 1975, 8, 267-275.	1.4	51
447	Altered metabolism of carcinoembryonic antigen in hamsters bearing GW-39 tumours. <i>Nature</i> , 1974, 249, 837-838.	27.8	14
448	In vivo hybridisation of human tumour and normal hamster cells. <i>Nature</i> , 1974, 250, 649-651.	27.8	153
449	Synthesis of Carcinoembryonic Antigen in vitro. <i>Nature: New Biology</i> , 1972, 239, 189-190.	4.5	27
450	Stathmokinetic effect of colcemid on a presumptive human-hamster hybrid tumor, GW-478. <i>Experimental and Molecular Pathology</i> , 1971, 14, 134-137.	2.1	8

#	ARTICLE	IF	CITATIONS
451	Synergistic effects of X-rays and drugs on a human tumor xenograft, GW-39. European Journal of Cancer, 1970, 6, 73-80.	0.9	8
452	Identity and nature of isolated lymphoid tumors (so-called nodal hyperplasia, hamartoma, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 studies. Cancer, 1970, 25, 1286-1300.	4.1	64
453	Retention of Human Properties by a Xenografted Human Colonic Tumor, GW-77, Propagated in Unconditioned Hamsters. Experimental Biology and Medicine, 1970, 135, 657-659.	2.4	12
454	In vivo proliferation of heterotransplanted human cancer cells. European Journal of Cancer, 1967, 3, 315-319.	0.9	17
455	Chemotherapy of two morphologically similar human tumors growing in the cheek pouch of the golden hamster: H. Ad. No. 1 and GW-39. European Journal of Cancer, 1967, 3, 95-101.	0.9	21
456	GW-39: A NEW HUMAN TUMOR SERIALY TRANSPLANTABLE IN THE GOLDEN HAMSTER. Transplantation, 1966, 4, 760-763.	1.0	86
457	Radioactive antibodies: Selective targeting and treatment of cancer and other diseases. , 0, , 10-29.		4